Abstract
Artemisinin-based combination therapies (ACTs) have demonstrated in vitro inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Artemisinins have also shown anti-inflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the development of severe coronavirus disease 2019 (COVID-19). There is now sufficient evidence for the effectiveness of ACTs, and in particular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.
Keywords: SARS-CoV-2; antimalarial; antiviral; artesunate/pyronaridine; cytokine storm; drug repurposing.
All Keywords
【저자키워드】 SARS-CoV-2, Cytokine storm, Antiviral, antimalarial, artesunate/pyronaridine, drug repurposing., 【초록키워드】 COVID-19, coronavirus disease, Drug repurposing, Coronavirus disease 2019, Cytokine storm, coronavirus, Anti-inflammatory effects, Antiviral, IL-6, interleukin-6, combination therapy, cytokine, in vitro, severe acute respiratory syndrome Coronavirus, antimalarial, Artemisinin, artesunate/pyronaridine, interleukin, Effectiveness, Clinical studies, respiratory, pyronaridine, clinical study, Evidence, artemisinins, artesunate, Support, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, severe coronavirus disease, combination therapies, COVID-19 infections, acts, shown, demonstrated, 【제목키워드】 COVID-19, repurposing,
【저자키워드】 SARS-CoV-2, Cytokine storm, Antiviral, antimalarial, artesunate/pyronaridine, drug repurposing., 【초록키워드】 COVID-19, coronavirus disease, Drug repurposing, Coronavirus disease 2019, Cytokine storm, coronavirus, Anti-inflammatory effects, Antiviral, IL-6, interleukin-6, combination therapy, cytokine, in vitro, severe acute respiratory syndrome Coronavirus, antimalarial, Artemisinin, artesunate/pyronaridine, interleukin, Effectiveness, Clinical studies, respiratory, pyronaridine, clinical study, Evidence, artemisinins, artesunate, Support, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, severe coronavirus disease, combination therapies, COVID-19 infections, acts, shown, demonstrated, 【제목키워드】 COVID-19, repurposing,
{{{ 추상적인 }}}
아르테미시닌 기반 조합 요법(ACT)은 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)의 시험관 내 억제를 입증했습니다. 아르테미시닌은 또한 2019년 중증 코로나바이러스(COVID-19) 발병에 핵심적인 역할을 하는 인터루킨-6(IL-6)의 억제를 포함한 항염증 효과를 보였습니다. 현재 COVID-19 감염에 대한 임상 연구를 뒷받침하기 위해 ACT, 특히 아르테수네이트/피로나리딘의 효과에 대한 충분한 증거가 있습니다.
{{ 키워드: }} SARS-CoV-2; 항말라리아제; 항바이러스제; 아르테수네이트/피로나리딘; 사이토카인 폭풍; 약물 용도 변경.